EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas

R Izu-Belloso, I Gainza-Apraiz, P Ortiz-Romero, O Servitje-Bedate, R Fernández de Misa-Cabrera, Y Peñate, B Hernandez-Machin, T Estrach-Panella, M Llamas-Velasco, J I Yanguas-Bayona, M Morillo-Andujar, E Acebo-Mariñas und 10 weitere

Actas Dermo-Sifiliográficas · 2024

DOI: 10.1016/j.ad.2023.12.007 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Actas Dermo-Sifiliográficas, 2024. Verfasst von R Izu-Belloso und 21 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Basurto, Bilbao, Spain. Electronic address: rosamaria.izubelloso@osakidetza.eus. Hauptthemen laut MEDLINE: Bexarotene, Skin Neoplasms, Tetrahydronaphthalenes, Mycosis Fungoides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Bexarotene has been approved to treat advanced stage cutaneous T-cell lymphomas (CTCL) since 1999. However, very few data have been published on its long-term safety and efficacy profile. The aim of this study is to determine the tolerability to bexarotene and outcomes by collecting the 2nd largest case series to date on its long-term use vs CTCL. MATERIAL AND METHOD: This was a multicenter retrospective review of 216 patients with mycosis fungoides (174), or Sézary syndrome (42) on a 10-year course of bexarotene alone or in combination with other therapies at 19 tertiary referral teaching hospitals. RESULTS: A total of 133 men (62%) and 83 women (38%) were included, with a mean age of 63.5 year (27-95). A total of 45% were on bexarotene monotherapy for the entire study period, 22% started on bexarotene but eventually received an additional therapy, 13% were on another treatment but eventually received bexarotene while the remaining 20% received a combination therapy since the beginning. The median course of treatment was 20.78 months (1-114); and the overall response rate, 70.3%. Complete and partial response rates were achieved in 26% and 45% of the patients, respectively. Treatment was well tolerated, being the most common toxicities hypertriglyceridemia (79%), hypercholesterolemia (71%), and hypothyroidism (52%). No treatment-related grade 5 adverse events were reported. CONCLUSIONS: Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BexaroteneSkin NeoplasmsTetrahydronaphthalenesMycosis FungoidesSezary SyndromeHumansMaleFemaleAgedRetrospective StudiesMiddle AgedAged, 80 and overAdultSpainLymphoma, T-Cell, CutaneousTreatment OutcomeAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

BexaroteneBexarotenoCutaneous T-cell lymphomaLinfoma cutáneo de células TMicosis fungoideMycosis fungoidesRetinoidRetinoideSézary syndromeSíndrome de Sézary

Substanzen

BexaroteneTetrahydronaphthalenes

Autor:innen und Institutionen

  • Hospital Universitario Basurto, Bilbao, Spain. Electronic address: rosamaria.izubelloso@osakidetza.eus.
  • Hospital Universitario Basurto, Bilbao, Spain.
  • Hospital 12 de Octubre, Madrid, Spain.
  • Hospital de Bellvitge, Barcelona, Spain.
  • Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
  • Complejo Hospitalario Universitario Insular Materno-Infantil, Gran Canaria, Spain.

Zitieren

APA

Izu-Belloso, R., Gainza-Apraiz, I., Ortiz-Romero, P., Servitje-Bedate, O., Fernández de Misa-Cabrera, R., Peñate, Y., Hernandez-Machin, B., Estrach-Panella, T., Llamas-Velasco, M., Yanguas-Bayona, J. I., Morillo-Andujar, M., Acebo-Mariñas, E., Perez-Gala, S., Armario-Hita, J. C., Sanchez-Sambucety, P., Ortiz-Brugues, A., Eguren-Michelena, C., Bielsa-Marsol, I., Lopez-Pestaña, A., …, & Lopez-Lerma, I. (2024). Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2023.12.007

Vancouver

Izu-Belloso R, Gainza-Apraiz I, Ortiz-Romero P, Servitje-Bedate O, Fernández de Misa-Cabrera R, Peñate Y, et al. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas. Actas Dermo-Sifiliográficas. 2024. doi:10.1016/j.ad.2023.12.007

BibTeX
@article{IzuBelloso2024,
  author = {Izu-Belloso, R and Gainza-Apraiz, I and Ortiz-Romero, P and Servitje-Bedate, O and Fernández de Misa-Cabrera, R and Peñate, Y and Hernandez-Machin, B and Estrach-Panella, T and Llamas-Velasco, M and Yanguas-Bayona, J I and Morillo-Andujar, M and Acebo-Mariñas, E and Perez-Gala, S and Armario-Hita, J C and Sanchez-Sambucety, P and Ortiz-Brugues, A and Eguren-Michelena, C and Bielsa-Marsol, I and Lopez-Pestaña, A and Blanes-Martinez, M and Fernandez-Guarino, M and Lopez-Lerma, I},
  title = {Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2024},
  doi = {10.1016/j.ad.2023.12.007}
}
Kostenlos starten →